Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Aliza Yong"'
Autor:
Diar Aziz, Neil Portman, Kristine J. Fernandez, Christine Lee, Sarah Alexandrou, Alba Llop-Guevara, Zoe Phan, Aliza Yong, Ashleigh Wilkinson, C. Marcelo Sergio, Danielle Ferraro, Dariush Etemadmoghadam, David D. Bowtell, kConFab Investigators, Violeta Serra, Paul Waring, Elgene Lim, C. Elizabeth Caldon
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-14 (2021)
Abstract Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly to targeted therapies and chemotherapies. In order to define therapeutically targetable subsets of BLBC we examined two markers: cyclin E1 and BRCA1 loss. In
Externí odkaz:
https://doaj.org/article/6daf1a428240435b83fc21ea45524a31
Autor:
Neil Portman, Heloisa H. Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine J. Fernandez, Kee Ming Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne D. Tilley, Alex Swarbrick, C. Elizabeth Caldon, Elgene Lim
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
Abstract Background Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed via upregulation of
Externí odkaz:
https://doaj.org/article/b6f51a6926794f258d9ad544dc70f957
Autor:
Sarah Alexandrou, Aliza Yong, C. Elizabeth Caldon, Dariush Etemadmoghadam, kConFab Investigators, Zoe Phan, Danielle Ferraro, Elgene Lim, Paul Waring, Neil Portman, Diar Aziz, Kristine J. Fernandez, C. Marcelo Sergio, David D.L. Bowtell, Christine S. L. Lee, Wilkinson A, Violeta Serra, Alba Llop-Guevara
Publikováno v:
NPJ Breast Cancer
npj Breast Cancer, Vol 7, Iss 1, Pp 1-14 (2021)
npj Breast Cancer, Vol 7, Iss 1, Pp 1-14 (2021)
Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly to targeted therapies and chemotherapies. In order to define therapeutically targetable subsets of BLBC we examined two markers: cyclin E1 and BRCA1 loss. In high grad
Autor:
Joanna Achinger-Kawecka, Clare Stirzaker, Neil Portman, Elyssa Campbell, Kee-Ming Chia, Qian Du, Geraldine Laven-Law, Shalima S. Nair, Aliza Yong, Ashleigh Wilkinson, Samuel Clifton, Heloise H. Milioli, Sarah Alexandrou, C. Elizabeth Caldon, Jenny Song, Amanda Khoury, Braydon Meyer, Julia M.W. Gee, Anthony Schmitt, Emily S. Wong, Theresa E. Hickey, Elgene Lim, Susan J. Clark
Three-dimensional (3D) epigenome remodelling is emerging as an important mechanism of gene deregulation in cancer. However, its potential as a target to overcome cancer therapy resistance remains largely unaddressed. Here we show that treatment of en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f165cb5b806d5cd596741306b58a3a12
https://doi.org/10.1101/2021.06.21.449340
https://doi.org/10.1101/2021.06.21.449340
Autor:
Aliza Yong, Alexander Swarbrick, Liz Caldon, Kee Ming Chia, Wayne D. Tilley, Geraldine Laven-Law, Neil Portman, T Hickey, Elgene Lim, Heloisa Helena Milioli
Publikováno v:
Cancer Research. 79:P6-20
Introduction Resistance to endocrine therapy is a major clinical problem in estrogen receptor positive (ER+) breast cancer. The androgen receptor (AR) is expressed in ˜90% of all ER+ breast cancers and high expression of AR is associated with a bett
Autor:
Allegra Freelander, Geraldine Laven-Law, Leila Eshraghi, Kee Ming Chia, Marie Pickering, Aliza Yong, Ashleigh Wilkinson, Sarah Alexandrou, C. Elizabeth Caldon, Theresa E Hickey, Wayne D Tilley, Elgene Lim
Publikováno v:
Cancer Research. 82:PD2-02
Resistance to standard-of care-therapies is a significant clinical challenge in estrogen receptor positive (ER+) breast cancer. Cyclin dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapies (ET) is the current standard-of-c
Autor:
Kee Ming Chia, Sarah Alexandrou, C. Elizabeth Caldon, Ensar Halilovic, Alexander Swarbrick, Rhiannon Coulson, Wayne D. Tilley, Heloisa Helena Milioli, Aliza Yong, Ygal Haupt, Neil Portman, Elgene Lim, Andrew Parker, Sue Haupt, Davendra Segara, Kristine J. Fernandez
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
BackgroundResistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed via upregulation of its key re
Autor:
Davendra Segara, Elgene Lim, Kristine J. Fernandez, C. Elizabeth Caldon, Aliza Yong, Andrew Parker, Kee Ming Chia, Heloisa Helena Milioli, Ygal Haupt, Sue Haupt, Rhiannon Coulson, Neil Portman, Sarah Alexandrou, Ensar Halilovic, Wayne D. Tilley, Alexander Swarbrick
BackgroundResistance to endocrine therapy is a major clinical challenge in the management of estrogen receptor (ER)-positive breast cancer. In this setting p53 is frequently wildtype and its activity may be suppressed via upregulation of its key regu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b923afc79f5f41e0aa7626254d04d2a5
https://doi.org/10.1101/2020.06.09.140921
https://doi.org/10.1101/2020.06.09.140921
Autor:
Investigators k, Kristine J. Fernandez, Serra, Paul Waring, Elgene Lim, C.E. Caldon, Danielle Ferraro, Dariush Etemadmoghadam, Wilkinson A, Diar Aziz, Sarah Alexandrou, Claudio M Sergio, Christine S. L. Lee, Aliza Yong, David D.L. Bowtell, Alba Llop-Guevara, Neil Portman
Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly to targeted therapies and chemotherapies. In order to define therapeutically targetable subsets of BLBC we examined two markers: cyclin E1 and BRCA1 loss. In high grad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0fbfc75badafe8d8f196bcd847b1e34
Autor:
Heloisa Helena Milioli, Sue Haupt, Aliza Yong, Sarah Alexandrou, C. Elizabeth Caldon, Rhiannon Coulson, Neil Portman, Ygal Haupt, Elgene Lim, Natasha Lam
Publikováno v:
Oncology Abstracts.